Seres Therapeutics (MCRB) Misses Q2 EPS by 218c
Seres Therapeutics (NASDAQ: MCRB) reported Q2 EPS of ($2.27), $2.18 worse than the analyst estimate of ($0.09).
For earnings history and earnings-related data on Seres Therapeutics (MCRB) click here.
Seres Therapeutics (NASDAQ: MCRB) reported Q2 EPS of ($2.27), $2.18 worse than the analyst estimate of ($0.09).
For earnings history and earnings-related data on Seres Therapeutics (MCRB) click here.